VRCA - ヴェリカ・ファ―マシュ―ティカルズ （Verrica Pharmaceuticals Inc.） ヴェリカ・ファ―マシュ―ティカルズ

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can’t just introduce health-related products directly to the market. Instead, they must undergo intensive clinical tests to ensure broader public safety. During these processes, plenty of things can go wrong, thus introducing volatility to the space. Still, investors who want to maximize the return potential of their speculation-earmarked funds should consider the best biotech stocks for 2023. Specifically, this list will target decently stable enterprises with massive upside targets, as determined by Wall Street analysts. And by massive, I really mean that. The majority of these biotech stocks with breakthrough products feature price targets that imply triple-digit percentage gains. And one, in particular, enjoys a 733% upside forecast. Of course, the other side to this equation is that you must be willing to accept serious risks. If that’s you, these are the biotech stocks with high growth potential.

Upgrades Guggenheim upgraded the previous rating for Immunovant Inc (NASDAQ: IMVT ) from Neutral to Buy. In the third quarter, Immunovant showed an EPS of $0.49, compared to $0.36 from the year-ago quarter. The current stock performance of Immunovant shows a 52-week-high of $20.24 and a 52-week-low of $3.15. Moreover, at the end of the last trading period, the closing price was at $18.43. For Proto Labs Inc (NYSE: PRLB ), Benchmark upgraded the previous rating of Hold to Buy. Proto Labs earned $0.26 in the fourth quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.14 and a 52-week-low of $22.04. Proto Labs closed at $34.43 at the end of the last trading period. According to CLSA, the prior rating for Gaotu Techedu Inc (NYSE: GOTU ) was changed from Underperform to Outperform. For the third quarter, Gaotu Techedu had an EPS of $0.02, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $4.50 and a 52-week-low of $0.64.

Verrica Pharmaceuticals (VRCA) added ~7% pre-market Monday after RBC Capital Markets upgraded itciting a potential FDA nod for its lead asset VP-102. Read the full story here.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares made only slight gians Tuesday on word it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. VP-102 could potentially be the first product approved by the FDA to treat molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Upon resubmission of the NDA for VP-102, Verrica intends to seek conditional approval to market VP-102 in the United States under the brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. “We are pleased with the hard work and commitment from the entire Verrica team that has allowed us to resubmit the NDA for VP-102 for molluscum,” said CEO Ted White. “We believe the successful tech transfer of our bulk solution manufacturing addresses the only deficiency in our previous filing that resulted in our Complete Response Letter last year.

Verrica Pharmaceuticals press release (NASDAQ:VRCA): Q3 GAAP EPS of $0.00 beats by $0.14.Revenue of $8.3M beats by $4.05M.

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can’t just introduce health-related products directly to the market. Instead, they must undergo intensive clinical tests to ensure broader public safety. During these processes, plenty of things can go wrong, thus introducing volatility to the space. Still, investors who want to maximize the return potential of their speculation-earmarked funds should consider the best biotech stocks for 2023. Specifically, this list will target decently stable enterprises with massive upside targets, as determined by Wall Street analysts. And by massive, I really mean that. The majority of these biotech stocks with breakthrough products feature price targets that imply triple-digit percentage gains. And one, in particular, enjoys a 733% upside forecast. Of course, the other side to this equation is that you must be willing to accept serious risks. If that’s you, these are the biotech stocks with high growth potential.

Upgrades Guggenheim upgraded the previous rating for Immunovant Inc (NASDAQ: IMVT ) from Neutral to Buy. In the third quarter, Immunovant showed an EPS of $0.49, compared to $0.36 from the year-ago quarter. The current stock performance of Immunovant shows a 52-week-high of $20.24 and a 52-week-low of $3.15. Moreover, at the end of the last trading period, the closing price was at $18.43. For Proto Labs Inc (NYSE: PRLB ), Benchmark upgraded the previous rating of Hold to Buy. Proto Labs earned $0.26 in the fourth quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.14 and a 52-week-low of $22.04. Proto Labs closed at $34.43 at the end of the last trading period. According to CLSA, the prior rating for Gaotu Techedu Inc (NYSE: GOTU ) was changed from Underperform to Outperform. For the third quarter, Gaotu Techedu had an EPS of $0.02, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $4.50 and a 52-week-low of $0.64.

Verrica Pharmaceuticals (VRCA) added ~7% pre-market Monday after RBC Capital Markets upgraded itciting a potential FDA nod for its lead asset VP-102. Read the full story here.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares made only slight gians Tuesday on word it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. VP-102 could potentially be the first product approved by the FDA to treat molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Upon resubmission of the NDA for VP-102, Verrica intends to seek conditional approval to market VP-102 in the United States under the brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. “We are pleased with the hard work and commitment from the entire Verrica team that has allowed us to resubmit the NDA for VP-102 for molluscum,” said CEO Ted White. “We believe the successful tech transfer of our bulk solution manufacturing addresses the only deficiency in our previous filing that resulted in our Complete Response Letter last year.

Verrica Pharmaceuticals press release (NASDAQ:VRCA): Q3 GAAP EPS of $0.00 beats by $0.14.Revenue of $8.3M beats by $4.05M.

Upgrades Guggenheim upgraded the previous rating for Immunovant Inc (NASDAQ: IMVT ) from Neutral to Buy. In the third quarter, Immunovant showed an EPS of $0.49, compared to $0.36 from the year-ago quarter. The current stock performance of Immunovant shows a 52-week-high of $20.24 and a 52-week-low of $3.15. Moreover, at the end of the last trading period, the closing price was at $18.43. For Proto Labs Inc (NYSE: PRLB ), Benchmark upgraded the previous rating of Hold to Buy. Proto Labs earned $0.26 in the fourth quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.14 and a 52-week-low of $22.04. Proto Labs closed at $34.43 at the end of the last trading period. According to CLSA, the prior rating for Gaotu Techedu Inc (NYSE: GOTU ) was changed from Underperform to Outperform. For the third quarter, Gaotu Techedu had an EPS of $0.02, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $4.50 and a 52-week-low of $0.64.

Verrica Pharmaceuticals (VRCA) added ~7% pre-market Monday after RBC Capital Markets upgraded itciting a potential FDA nod for its lead asset VP-102. Read the full story here.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares made only slight gians Tuesday on word it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. VP-102 could potentially be the first product approved by the FDA to treat molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Upon resubmission of the NDA for VP-102, Verrica intends to seek conditional approval to market VP-102 in the United States under the brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. “We are pleased with the hard work and commitment from the entire Verrica team that has allowed us to resubmit the NDA for VP-102 for molluscum,” said CEO Ted White. “We believe the successful tech transfer of our bulk solution manufacturing addresses the only deficiency in our previous filing that resulted in our Complete Response Letter last year.

Verrica Pharmaceuticals press release (NASDAQ:VRCA): Q3 GAAP EPS of $0.00 beats by $0.14.Revenue of $8.3M beats by $4.05M.

WILMINGTON, DE / ACCESSWIRE / October 6, 2022 / Transparency Market Research Inc. - Emergence of microwave technology is transforming the warts therapeutics market landscape. The limited options for treatment of warts is driving medtech companies to attain effectiveness of microwave technology. To this end, some companies have been successful in development of microwave technology to stimulate the body''s immune system to clear human papillomavirus (HPV) which is the cause for warts. The ban of use of liquid nitrogen in clinics for warts by some governments, has provided medtech companies the opportunity to improve microwave technology. The warts therapeutics market is estimated to be nearly valued at US$ 2.4 Bn by 2030. Efficacy of telemedicine during COVID-19 era has led to increased consumer confidence in remote consultation for warts therapeutics. As such, demand for telehealth technology for warts therapeutics is anticipated to rise at a staggering pace in the upcoming years. The development of telemedicine apps is assisting to provide quality medical care for warts, especially genital warts, and thus shape the future growth of warts therapeutics market.